EMERYVILLE, Calif., Aug. 25, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSEAmex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, is highlighted in the August 2011 issue of Cataract & Refractive Surgery Today.
